Avid Bioservices Inc (CDMO)

[JamesGMS]

Hello Ent, re your post excerpted in relevant part below:

We see statistically significant differences in many instances that do not translate into a cost-effect significant improvement in quality of life. In other words, OS might be extended from 6 months to 8 months, which might attain statistical significance, but is not a marketable difference in treatment.

Remember we agree on your issue re treating advanced lung cancer - but I do have to take serious exception to your statement highlighted above in red - as we've discussed before, we are dealing with incremental improvements to the treatment of all kinds of cancers - and no, they of course do not offer a cure and in most cases not even a truly significant improvement to quality of life - but to say they do not present a "marketable difference in treatment" is quite simply incorrect - the most recent example of course being BMY receiving accelerated approval for NSCLC for just a two month improvement in MOS - so "incremental" is most certainly "marketable."

Enjoy the rest of your day.

James